Mirabilis Medica Inc.
This article was originally published in Start Up
The outstanding success of Novacept, the developer of a device that enabled an office-based procedure for endometrial ablation, demonstrates that Ob-Gyns are eager to offer minimally-invasive, safe, and rapid procedures to their patients as an alternative to the two extremes of surgically removing the uterus or doing nothing. Now Mirabilis Medical, headed up by a Novacept co-founder, hopes to accomplish the same thing for uterine fibroids.
You may also be interested in...
The women's health opportunity in the US is $2.75 billion on an annual basis, and it's growing at a compounded rate of 16% per year. Looking forward, demographics, the aging of the population, and technological innovations will continue to fuel growth. New technologies promise to cause one particular category in women's health to blossom; the treatment of uterine fibroids. According to "Women's Health: US Markets for Benign Uterine Condition Management Products," a report recently published by the Medtech Insight division of Windhover Information Inc., the number of fibroid treatments is expected to increase at a compound annual rate of 21.3%. The report also discusses the markets for the treatment of menorrhagia and endometriosis.
The infertility market has historically been dominated by drugs. There have been few product opportunities on the medtech side, which has consisted of commodity products like syringes, petri dishes and microscopes. But that is changing; recently several new companies have been founded with technologies to improve the success rates of in vitro fertilization. VCs have also come to realize that infertility represents a premium, self-pay market for elective procedures.
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Start-Ups in Obesity," "New Technologies for Infertility," and "New Zealand Biotech." Plus these Start-Ups Across Health Care: Intelect Medical, N Spine, and Solace Pharmaceuticals.